Literature DB >> 21304479

IBD: of mice and men-shedding new light on IL-13 activity in IBD.

Silvio Danese1.   

Abstract

a recent study in a mouse model of colitis has demonstrated that interleukin (Il)‑13, through inhibition of the mixed type 1 and type 17 T‑helper cell inflammatory response, has a protective effect. the decoyreceptor Il‑13rα2 inhibits this protective effect, suggesting blockade of Il‑13rα2 as a potential therapy for patients with IBD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21304479     DOI： 10.1038/nrgastro.2011.17

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.

Authors:  Frank Heller; Ivan J Fuss; Edward E Nieuwenhuis; Richard S Blumberg; Warren Strober
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.

Authors:  Ivan J Fuss; Christoph Becker; Zhiqiong Yang; Catherine Groden; Ronald L Hornung; Frank Heller; Markus F Neurath; Warren Strober; Peter J Mannon
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

3.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.

Authors:  Frank Heller; Peter Florian; Christian Bojarski; Jan Richter; Melanie Christ; Bernd Hillenbrand; Joachim Mankertz; Alfred H Gitter; Nataly Bürgel; Michael Fromm; Martin Zeitz; Ivan Fuss; Warren Strober; Jörg D Schulzke
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  Critical role of IL-17 receptor signaling in acute TNBS-induced colitis.

Authors:  Zili Zhang; Mingquan Zheng; Julie Bindas; Paul Schwarzenberger; Jay K Kolls
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

5.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

6.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

Authors:  I Arijs; K Li; G Toedter; R Quintens; L Van Lommel; K Van Steen; P Leemans; G De Hertogh; K Lemaire; M Ferrante; F Schnitzler; L Thorrez; K Ma; X-Y R Song; C Marano; G Van Assche; S Vermeire; K Geboes; F Schuit; F Baribaud; P Rutgeerts
Journal:  Gut       Date:  2009-08-20       Impact factor: 23.059

8.  IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.

Authors:  Stefan Fichtner-Feigl; Cheryl A Young; Atsushi Kitani; Edward K Geissler; Hans-Jürgen Schlitt; Warren Strober
Journal:  Gastroenterology       Date:  2008-09-11       Impact factor: 22.682

9.  Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity.

Authors:  Mark S Wilson; Thirumalai R Ramalingam; Aymeric Rivollier; Kevin Shenderov; Margaret M Mentink-Kane; Satish K Madala; Allen W Cheever; David Artis; Brian L Kelsall; Thomas A Wynn
Journal:  Gastroenterology       Date:  2010-10-14       Impact factor: 22.682

Review 10.  Effector T cell plasticity: flexibility in the face of changing circumstances.

Authors:  Kenneth M Murphy; Brigitta Stockinger
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606
  10 in total
  4 in total

1.  Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice.

Authors:  Lihua Duan; Jie Chen; Hongwei Zhang; Heng Yang; Ping Zhu; Ali Xiong; Quansong Xia; Fang Zheng; Zheng Tan; Feili Gong; Min Fang
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

2.  Infection with murine norovirus 4 does not alter Helicobacter-induced inflammatory bowel disease in Il10(-/-) mice.

Authors:  Charlie C Hsu; Jisun Paik; Piper M Treuting; Audrey Seamons; Stacey M Meeker; Thea L Brabb; Lillian Maggio-Price
Journal:  Comp Med       Date:  2014-08       Impact factor: 0.982

3.  Circulatory antigen processing by mucosal dendritic cells controls CD8(+) T cell activation.

Authors:  Sun-Young Chang; Joo-Hye Song; Bayasi Guleng; Carmen Alonso Cotoner; Seiji Arihiro; Yun Zhao; Hao-Sen Chiang; Michael O'Keeffe; Gongxian Liao; Christopher L Karp; Mi-Na Kweon; Arlene H Sharpe; Atul Bhan; Cox Terhorst; Hans-Christian Reinecker
Journal:  Immunity       Date:  2012-12-13       Impact factor: 31.745

Review 4.  Current stage in inflammatory bowel disease: What is next?

Authors:  Gonzalo Jesús Gómez-Gómez; Ángeles Masedo; Carmen Yela; Maria del Pilar Martínez-Montiel; Begoña Casís
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.